The natalizumab wearing-off effect
Open Access
- 22 October 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 93 (17) , E1579-E1586
Abstract
Objective Natalizumab is effective in treating relapsing-remitting multiple sclerosis (RRMS). However, many patients report an increase of multiple sclerosis symptoms at the end of the natalizumab cycle: a wearing-off effect. The objective of this study was to evaluate the prevalence of the wearing-off effect in patients with standard and extended intervals and to study possible associations with pharmacokinetic/dynamic measurements and patient characteristics in a prospective, monocenter, cross-sectional cohort study. Methods Patients with RRMS, with a minimum of 6 natalizumab infusions, were asked to complete 3 questionnaires: the Multiple Sclerosis Impact Scale, the 36-Item Short Form Health Survey, and a general questionnaire regarding the wearing-off effect. Natalizumab concentration and α4-integrin receptor saturation were measured before redosing. Results Ninety-three patients were included. A total of 54% experienced a wearing-off effect during natalizumab treatment and 32% experienced a current wearing-off effect at time of measurement. The self-reported wearing-off effect was not associated with natalizumab concentration nor with α4-integrin receptor saturation. The wearing-off effect was more frequently reported in the standard interval group (39%) than in the extended interval group (19%); the duration of symptoms was comparable between both groups. The wearing-off effect was not associated with number of infusions, disease duration, age, or sex. Conclusion The wearing-off effect is a frequently reported phenomenon but is unlikely to reflect a nonoptimal pharmacokinetic/dynamic state. We did not find risk factors predicting the wearing-off effect.Keywords
This publication has 18 references indexed in Scilit:
- Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing CycleInternational Journal of MS Care, 2014
- Extended interval dosing of natalizumab: a two-center, 7-year experienceTherapeutic Advances in Neurological Disorders, 2014
- Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life SettingPLOS ONE, 2013
- Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibodyAnalytical Biochemistry, 2011
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionNeurology, 2009
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?Journal of Neurology, Neurosurgery & Psychiatry, 2006
- IMMUNOLOGY OF MULTIPLE SCLEROSISAnnual Review of Immunology, 2005
- Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MSExpert Review of Neurotherapeutics, 2004
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992